<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821285</url>
  </required_header>
  <id_info>
    <org_study_id>2215CE</org_study_id>
    <nct_id>NCT03821285</nct_id>
  </id_info>
  <brief_title>Respiratory Function in Patients With Post-tuberculosis Lung Impairment</brief_title>
  <official_title>Evaluation of Respiratory Function in Patients With Post-tuberculosis Lung Impairment After Pulmonary Tuberculosis Treatment or After Spontaneous Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria di Sassari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due&#xD;
      to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation&#xD;
      has provided clear evidence that TB is definitively responsible for lung function impairment.&#xD;
      Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or&#xD;
      spontaneous healing should be considered as part of clinical care. Unfortunately, few studies&#xD;
      are available in the literature investigating the physiopathology of lung damage, its impact&#xD;
      on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of&#xD;
      a PR program.Objectives of this prospective multicentre international study are: Primary&#xD;
      Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung&#xD;
      impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing.&#xD;
      Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle&#xD;
      fatigue, quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods Respiratory functional parameters at baseline and at the end of the 15 sessions&#xD;
      rehabilitation programme (RP) will be collected at the participating Centre. Follow-up visit&#xD;
      1 year after completion of RP Baseline assessment&#xD;
&#xD;
        1. After signature of the informed consent to the study, patients will undergo a&#xD;
           Pre-screening Visit: data on medical history, current pharmacological therapies, smoking&#xD;
           (pack/year), vaccinations, physical examination, vital parameters (blood pressure, heart&#xD;
           rate, respiratory rate, oxygen saturation in arterial blood), co-morbidities and Mini&#xD;
           Mental State Examination will be collected.&#xD;
&#xD;
        2. Screening Visit (before the RP), during the visit the following data will be collected:&#xD;
           number of TB disease episodes, detailed data on the last TB episode (age at onset of TB&#xD;
           symptoms, age at TB diagnosis, anti-TB treatment duration, anti-TB drugs administered,&#xD;
           socio-economic conditions, education level, physical examination, vital parameters,&#xD;
           oxygen saturation in arterial blood, heart rate and respiratory rate). Pulmonary&#xD;
           rehabilitation program tailored according to specific patient's needs.&#xD;
&#xD;
        3. Baseline assessment of respiratory function: arterial blood gas (ABG) analysis,&#xD;
           spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), overnight&#xD;
           oximetry, electrocardiogram (ECG), chest X-ray (CXR), High-resolution computed&#xD;
           tomography (HRCT)&#xD;
&#xD;
        4. Assessment of the rehabilitation programme: functional evaluation (6MWT), muscle&#xD;
           strength evaluation (five-repetition sit-to-stand test (5STS)), respiratory muscle&#xD;
           strength (maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)),&#xD;
           symptoms evaluation (Dyspnea: Medical Research Council Questionnaire (MRC), Modified&#xD;
           Borg pre/post 6MWT, Baseline and Transition Dyspnea Indexes (BDI-TDI) and Fatigue:&#xD;
           Modified Borg pre/post 6MWT)&#xD;
&#xD;
        5. Assessment of the Quality of Life (QoL): CAT and St George's Respiratory Questionnaire.&#xD;
&#xD;
      Final assessment:&#xD;
&#xD;
      A final assessment will be done at the end of the rehabilitation programme and will include:&#xD;
&#xD;
      c) Only ABG, spirometry and DLCO d) and e).&#xD;
&#xD;
      Pulmonary rehabilitation programme&#xD;
&#xD;
      PR programme will include:&#xD;
&#xD;
      At least 15 aerobic-training sessions by cycle ergometer supervised by a respiratory&#xD;
      therapist (5 session per week, 30 minutes each: 5 minutes warm up, 20 minutes training and 5&#xD;
      minutes warm-down) at constant load (calculated with Hill equation, Hill K, et al. Estimating&#xD;
      maximum work rate during incremental cycle ergometry testing from six-minute walk distance in&#xD;
      patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil.&#xD;
      2008;89(9):1782-7.) with an adherence of at least 80%.&#xD;
&#xD;
        1. At least 15 strength-training sessions for peripheral muscles (30 minutes calisthenics&#xD;
           exercise) with an adherence of at least 80%.&#xD;
&#xD;
        2. At least 3 face to face and/or group educational sessions, for:&#xD;
&#xD;
             -  Optimization of inhalation techniques&#xD;
&#xD;
             -  Exercise training and maintenance programs&#xD;
&#xD;
             -  Daily physical activity&#xD;
&#xD;
             -  Airways clearance techniques&#xD;
&#xD;
             -  Long oxygen therapy home management.&#xD;
&#xD;
        3. According to individual needs, the PR program should include:&#xD;
&#xD;
             -  airways clearance techniques&#xD;
&#xD;
             -  inspiratory muscles training (with Threshold®)&#xD;
&#xD;
      Monitoring Anonymous data will be collected in a common electronic format (excel database).&#xD;
&#xD;
      Adverse events (AEs) and severe adverse events (SAEs) will be reported and registered.&#xD;
&#xD;
      Follow-up&#xD;
&#xD;
      Follow-up visit 1 year after completion of RP will include:&#xD;
&#xD;
      c) Only ABG, spirometry, DLCO and overnight oximetry d) and e) Statistical analysis A&#xD;
      two-tailed p-value less than 0.05 will be considered statistically significant.&#xD;
&#xD;
      Qualitative and quantitative variables will be described with absolute and relative&#xD;
      (percentages) frequencies and means (standard deviations -SD) or medians (interquartile&#xD;
      ranges -IQR) depending on their normality, respectively. The mean difference between the two&#xD;
      study groups in the 6MWT will be evaluated using the Student's t-test. Differences in the&#xD;
      variables associated to the secondary objectives will be evaluated using the Chi-square or&#xD;
      Student's t-test for qualitative and quantitative variables. A two-tailed p-value less than&#xD;
      0.05 will be considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">February 14, 2019</start_date>
  <completion_date type="Anticipated">January 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multicentre international</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-min walking test</measure>
    <time_frame>1 year</time_frame>
    <description>Exercise capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dyspnoea</measure>
    <time_frame>1 year</time_frame>
    <description>Modified BORG scale (0-10) 0 better, 10 worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle fatigue</measure>
    <time_frame>1 year</time_frame>
    <description>Modified Borg scale (0-10) 0 better, 10 worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health related quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>st. George Respiratory Questionnaire 0 better, 100 worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health status</measure>
    <time_frame>1 year</time_frame>
    <description>COPD Assessment test-CAT (0-40) 0 better, 40 worse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Diseases, Obstructive</condition>
  <condition>Pulmonary Rehabilitation</condition>
  <condition>Lung TB</condition>
  <arm_group>
    <arm_group_label>pulmonary rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary rehabilitation program</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Rehabilitation</intervention_name>
    <description>Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training</description>
    <arm_group_label>pulmonary rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with post-TB lung impairment after completion of pulmonary tuberculosis&#xD;
        treatment - Patients with post- TB impairment after spontaneous healing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable medical condition&#xD;
&#xD;
          -  Musculoskeletal disorders contraindicating participation in the PR program&#xD;
&#xD;
          -  Cognitive impairment (Mini Mental State Examination &lt;22)&#xD;
&#xD;
          -  Unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovan Battista Migliori, Prof</last_name>
    <role>Study Director</role>
    <affiliation>ICS Maugeri, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Visca, Dr</last_name>
    <phone>+390331829111</phone>
    <email>dina.visca@icsmaugeri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabetta Zampogna, Dr</last_name>
    <phone>+390331829503</phone>
    <email>elisabetta.zampogna@icsmaugeri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICS Maugeri, IRCCS</name>
      <address>
        <city>Tradate</city>
        <state>Varese</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Visca, Dr</last_name>
      <phone>+390331829111</phone>
      <email>dina.visca@icsmaugeri.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisabetta Zampogna, Dr</last_name>
      <phone>+390331829503</phone>
      <email>elisabetta.zampogna@icsmaugeri.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24. Review.</citation>
    <PMID>29487031</PMID>
  </reference>
  <results_reference>
    <citation>Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Pérez-Padilla R, Spanevello A, Migliori GB. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226. Review. English, Portuguese.</citation>
    <PMID>27812638</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Dina Visca</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>Pulmonary rehabilitation</keyword>
  <keyword>Lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

